Landos Biopharma Inc

Landos Biopharma — Investor Presentation (May 2023)

23 slides from Landos Biopharma's investor presentation, May 12, 2023

  1. Slide 1: Corporate Overview

    Slide 1: Corporate Overview

    May 2023 Clinical stage biopharmaceutical company focused on developing first-in-class, oral therapeutics for autoimmune disease Corporate Overview Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, pla

  3. Slide 3: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Slide 3: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising safety profile and

  4. Slide 4: NX-13 Unique Bimodal MOA Targets NLRX1 Pathways for Treatment of UC

    Slide 4: NX-13 Unique Bimodal MOA Targets NLRX1 Pathways for Treatment of UC

    NX-13 Unique Bimodal MOA Targets NLRX1 Pathways for Treatment of Ulcerative Colitis (UC) Leber et al. J Immunology 2019 NX-13 is an oral, once-daily therapy being developed for moderate to severe UC Novel NLRX1 agonist Bimodal MOA aims to reduce reactive oxygen species intracellularly and inflammato

  5. Slide 5: Therapeutic Challenges Present Large Unmet Need for UC Patients

    Slide 5: Therapeutic Challenges Present Large Unmet Need for UC Patients

    Therapeutic Challenges Present Large Unmet Need for UC Patients Active UC Induction Therapy to reach clinical/endoscopic remission Maintenance Therapy to maintain clinical and endoscopic remission Insufficient response Relapse Ulcerative Colitis Chronic colonic inflammation with rectal bleeding and

  6. Slide 6: Current Therapies Focus Exclusively on Extracellular Actions or Signals

    Slide 6: Current Therapies Focus Exclusively on Extracellular Actions or Signals

    Current Therapies Focus Exclusively on Extracellular Actions or Signals Falling Short of Effectively Treating a Multifactorial Disease Like UC Global Data Report GDHC271PIDR; Chi, Cell & Mol Immuno 2022 Drug Classes MOA Extracellular (External) Intracellular (Internal) Environment Drug Classes MOA C

  7. Slide 7: Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy

    Slide 7: Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy

    Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy The intracellular immunometabolic state (the processing & using of energy through glycolysis or mitochondrial metabolism) provides a baseline, and can affect cellular response as pro- or anti-inflammator

  8. Slide 8: The Role of Immunometabolism in Immunology & UC

    Slide 8: The Role of Immunometabolism in Immunology & UC

    The Role of Immunometabolism in Immunology & UC Immunometabolic response in inflammatory diseases in the immunology universe & UC: Abnormal or imbalanced immune activation of the response resulting in over abundance of pro-inflammatory cells & cytokines with lack of anti-inflammatory control. In UC,

  9. Slide 9: Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response

    Slide 9: Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response

    Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response Aims to Control Multiple Factors in the UC Inflammation Cycle O’Neill et al. Nat. Rev. Immunol. 2016; Bittencourt et al. Inflammm Bowel Dis 2021; Chi, Cell & Mol Immuno 2022; ROS: Reactive Oxygen Species Metabol

  10. Slide 10: NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment

    Slide 10: NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment

    NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment to Reduce UC Inflammation Cycle Leber et al. J Immunology 2019; Leber et al. Front. Immuno 2018 Broad immune balance disfavors pro-inflammatory cells and cytokines with enhanced anti-inflammatory control Improved ep

  11. Slide 11: NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease

    Slide 11: NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease

    NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease Potential benefits may help transform the current treatment paradigm: Gut selective allowing target engagement with the GI tract Novel MOA, with oral, once-daily dosing MOA may allow for improved efficacy, greater mucosal healing,

  12. Slide 12: Attractive & Growing Market Opportunity in UC

    Slide 12: Attractive & Growing Market Opportunity in UC

    Attractive & Growing Market Opportunity in UC 2022 Decision Resource Group (Clarivate) UC Disease Landscape and Forecast 2020-2030 April 2023 Global Data Ulcerative Colitis: Eight-Market Drug Forecast & Market Analysis 2021-2031; Severe category includes fulminant Global UC Sales ($B): 2020 – 20301

  13. Slide 13: Phase 1b Study Design of NX-13 in Active UC

    Slide 13: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only 4 Weeks 1 Week Additional Information landosbiopharma.com/events-presentations (NX-13

  14. Slide 14: Phase 1b Results: Favorable Endoscopic and Histologic Responses

    Slide 14: Phase 1b Results: Favorable Endoscopic and Histologic Responses

    Phase 1b Results: NX-13 Demonstrated Favorable Endoscopic and Histologic Responses with Reductions in Multiple Clinical Measures After 4 Weeks Primary endpoints were safety and tolerability; Exploratory endpoints were efficacy and biomarkers; IR= Immediate Release; MR= modified release designed to d

  15. Slide 15: Phase 1b Results: Fast Onset of Action in Rectal Bleeding & Stool Frequency

    Slide 15: Phase 1b Results: Fast Onset of Action in Rectal Bleeding & Stool Frequency

    Phase 1b Results: Fast Onset of Action for NX-13 Supported Symptomatic Remission in Rectal Bleeding & Stool Frequency Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Rectal Bleeding Change from Baseline Stool Frequency Chang

  16. Slide 16: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement

    Slide 16: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement

    Phase 1b Results: NX-13 Was Well-Tolerated & Shows Promising Signs of Clinical Improvement in Active UC Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only NX-13 induced early signs of clinical improvement in patient’s symptoms

  17. Slide 17: NEXUS Phase 2 Proof of Concept Trial

    Slide 17: NEXUS Phase 2 Proof of Concept Trial

    NEXUS Phase 2 Proof of Concept Trial ClinicalTrials.gov Identifier: NCT05785715 Key Design Principles Blinded Powered Placebo Controlled Dose-Ranging Goal Evaluate safety, efficacy and pharmacokinetics of NX-13 in moderate to severe UC patients in 12-week induction trial Timing Initiated in Q2 2023;

  18. Slide 18: NEXUS Phase 2 Proof of Concept Study Design

    Slide 18: NEXUS Phase 2 Proof of Concept Study Design

    NEXUS Phase 2 Proof of Concept Study Design: NX-13 in Moderate to Severe UC Randomization n=80 Inclusion Moderate to Severe UC R NX-13 250mg IR n=32 NX-13 750mg IR n=32 Placebo n=16 Week 12 Week 52 EOT Day 1 Randomization Visit Inclusion Treatment Period 12 Weeks Long-Term Extension 40 Weeks R Rando

  19. Slide 19: Landos Pipeline Focused on Novel, Immunometabolic Targets

    Slide 19: Landos Pipeline Focused on Novel, Immunometabolic Targets

    Landos Pipeline Focused on Novel, Immunometabolic Targets Need a footnote describing the relationship with JH, also likely need a footnote for LianBio CANDIDATE INDICATION PRECLINICAL PRE-IND PHASE I PHASE II PHASE III NLRX1 Pathway NX-13 Ulcerative Colitis Crohn’s Disease LABP-66 Multiple Sclerosis

  20. Slide 20: Experienced Management Team in Immunology & Drug Development

    Slide 20: Experienced Management Team in Immunology & Drug Development

    Experienced Management Team in Immunology & Drug Development AMY PLACE, PHD Vice President, Project Leadership & Site Engagement GREGORY OAKES President & Chief Executive Officer FABIO CATALDI, MD Executive Vice President & Chief Medical Officer PATRICK TRUESDELL, CPA Vice President, Controller & Pr

  21. Slide 21: Top-Tier Advisory Teams

    Slide 21: Top-Tier Advisory Teams

    Top-Tier Advisory Teams GREGORY OAKES President & Chief Executive Officer CHRIS GARABEDIAN Chairman ROGER ADSETT Chief Operating Office of Insmed, Inc. FRED CALLORI Xontogeny, Perceptive Advisors TIAGO GIRÃO CFO of Proteovant Therapeutics TIM M. MAYLEBEN Director JEAN-FREDERIC COLOMBEL, MD Icahn Sch

  22. Slide 22: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Slide 22: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising safety profile and

  23. Slide 23: Thank you

    Slide 23: Thank you

    Thank you Contact: IR@landosbiopharma.com

Source: SEC EDGAR · 8-K filed May 12, 2023

More decks from Landos Biopharma Inc